Amneal Pharmaceuticals, Inc. AMRX Affordable Medicines — Restructuring and other charges
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RestructuringCharges.
The official record: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amneal Pharmaceuticals, Inc.'s affordable medicines — restructuring and other charges.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amneal Pharmaceuticals, Inc.'s affordable medicines — restructuring and other charges?
- Amneal Pharmaceuticals, Inc. (AMRX) reported affordable medicines — restructuring and other charges of $0 in Q1 2026.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s affordable medicines — restructuring and other charges?
- Over 3 years (2022 to 2025), Amneal Pharmaceuticals, Inc.'s affordable medicines — restructuring and other charges has grown at a 53.5% compound annual growth rate (CAGR), from $821K to $2.97M.
- What does affordable medicines — restructuring and other charges mean?
- Represents costs associated with organizational realignments, facility closures, or workforce reductions within the Affordable Medicines segment. These charges are typically incurred to improve long-term operational efficiency and cost structure.